Cortechs.ai | Cortechs.ai announces distribution partnership with EnvoyAI

Cortechs.ai announces distribution partnership with EnvoyAI

NeuroQuant is now available on EnvoyAI’s artificial intelligence Exchange.

Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce a distribution agreement with EnvoyAI, the leading artificial intelligence (AI) Exchange platform. NeuroQuant® and its LesionQuant™ module, Cortechs.ai’ leading MR image post-processing solutions, which expand physicians’ resources for assessing and quantifying brain structure and lesion volumes, is now available for purchase on the EnvoyAI Exchange.

Cortechs.ai solutions provide valuable, automated, quantitative data on brain structures and lesions, aiding radiologists in providing supportive information to neurologists and other healthcare professionals.  The solutions enhance clinical assessments, treatment planning, and disease progression monitoring of patients with neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, traumatic brain injury and more.

“We are entering an era of quantitative image analysis and EnvoyAI is excited to have Cortechs.ai’ FDA cleared quantitative imaging algorithms available through our Exchange,” said Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI. “Providing automated and objective measurements of brain structure volumes allows radiologists to provide more thorough assessments for patients and more complete reporting for referring physicians.”

“We are extremely pleased to partner with EnvoyAI and participate on their Exchange to provide access to quantitative imaging algorithms and data,” said Guri Stark, CEO of Cortechs.ai. “Over the last few years, NeuroQuant has become the standard for brain volume measurements. EnvoyAI increases the reach and impact of these algorithms to enhance healthcare globally.”

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top